

Editors-in-Chief
P. Boksa, PhD
R. Jooper, MD, PhD

Editor Emeritus
Y.D. Lapierre, MD

Associate Editors
P. Albert, PhD
M. Alda, MD
H. Anisman, PhD
M. Leyton, PhD
G.M. MacQueen, MD, PhD

Associate Editors (Statistics)
L. Annable, DipStat
N. Schmitz, PhD

Editorial Board conflict of interest statements are available at cma.ca/jpn

Editorial Advisory Board
G. Agam, PhD, Israel
S.L. Andersen, PhD, USA
M. Bourin, MD, France
S. Chattarji, PhD, India
K.P. Ebmeier, MD, United Kingdom
S. Floresco, PhD, Canada
T.S. Frodl, MD, Ireland
K.A. Hawkins, PsyD, USA
S. Kanba, MD, PhD, Japan
F. Kapczinski, MD, PhD, Brazil
T. Kato, MD, PhD, Japan
J. Mendlewicz, MD, Belgium
S.A. Montgomery, MD, United Kingdom
B. Müller-Oerlinghausen, MD, Germany
I. Nalepa, PhD, DSc, Poland
P. Ohrmann, MD, Germany
M. Pollack, MD, USA
G.J. Sarwer-Foner, MD, USA
P. Seeman, MD, PhD, Canada
A. Serretti, MD, Italy
D.J. Stein, MD, South Africa
K.G. Todd, PhD, Canada
V.K. Yeragani, MD, India

Submit your manuscript at
<http://mc.manuscriptcentral.com/jpn>

© 2013 Canadian Medical Association

ISSN 1180-4882

Publications Mail Agreement no. 41387051.
Return undeliverable Canadian copies to
CMA Member Service Centre, 1870 Alta Vista Dr.
Ottawa ON K1G 6R7; cmamsc@cma.ca.

Printed by Dollco Integrated Print Solutions,
Ottawa, Ont.
Appears in January, March, May, July,
September and November.

Journal of Psychiatry & Neuroscience

Official Journal of the Canadian College of Neuropsychopharmacology
March 2013 Vol. 38, No. 2 cma.ca/jpn

Editorial

- 75 A way forward for research on biomarkers for psychiatric disorders
P. Boksa

Commentary

- 78 Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin
S.N. Young

Review Paper

- 84 Overview of potential procedural and participant-related confounds for neuroimaging of the resting state
N.W. Duncan, G. Northoff

Research Papers

- 98 Dopamine D₂ and D₃ binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task
I. Suridjan, P. Rusjan, J. Addington, A.A. Wilson, S. Houle, R. Mizrahi
- 107 Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden
J. de Diego-Adeliño, M.J. Portella, B. Gómez-Ansón, O. López-Moruelo, M. Serra-Blasco, Y. Vives, D. Puigdemont, R. Pérez-Egea, E. Álvarez, V. Pérez
- 117 Recruitment of the left hemispheric emotional attention neural network in risk for and protection from depression
D.M. Lisiecka, A. Carballedo, A.J. Fagan, Y. Ferguson, J. Meaney, T. Frodl

- 129 Morphometric differences in central stress-regulating structures between women with and without borderline personality disorder
A. Kuhlmann, K. Bertsch, I. Schmidinger, P.A. Thomann, S.C. Herpertz

Psychopharmacology for the Clinician

- 144 Antidepressants and QTc prolongation
R.W. Lam

Managing Editor

Wendy Carroll
wendy.carroll@cma.ca
tel 800 663-7336 x2198

Editorial Coordinator

Melanie Slavitch
melanie.slavitch@cma.ca
tel 800 663-7336 x2182

Production

Kathryn A. Freamo
Nicole Barbeau, Carole Lalonde, Clara Walker

Associate Director, Publications

Holly Bodger

Online Publishing

James Harbinson, James Manship

Classified Advertising

Laurie McLeod, Susan Ritchie
613 731-8610 x2107/2041; fax 613 565-7488;
advertising@cma.ca

Display Advertising

Deborah Woodman

Display Advertising Sales

Blair Graham
416 850-1485; cell 416 560-0202
fax 416 850-2242; blair.graham@cma.ca

Trish Sullivan

cell 905 330-8770; trish.sullivan@cma.ca



All prescription drug advertisements have been cleared by the Pharmaceutical Advertising Advisory Board.

ASSOCIATION
MÉDICALE
CANADIENNE



CANADIAN
MEDICAL
ASSOCIATION

Published by the Canadian Medical Association

CMA Officers and Executives

Director and Publisher
Glenda Proctor

President
Anna Reid

Secretary General and CEO
Paul-Émile Cloutier

Vice-president, Professional Services and Leadership
Tim Smith


The *Journal of Psychiatry & Neuroscience* publishes original research articles and review papers in psychiatry and in neuroscience that advance our understanding of the mechanisms involved in the etiology and treatment of psychiatric disorders. This includes studies on patients with psychiatric disorders, healthy humans and experimental animals, as well as studies in vitro.

All editorial matter in the *Journal of Psychiatry & Neuroscience* represents the opinions of the authors and not necessarily those of CMA. CMA assumes no responsibility or liability for damages arising from any error or omission, or from use of any information or advice contained in the *Journal of Psychiatry & Neuroscience*, including articles, editorials, reviews, abstracts, letters and advertisements.




Journal of Psychiatry & Neuroscience

Visit *JPN's* archives
Full-text PDFs going back to 1991 are available at
pubmedcentral.com



Journal of Psychiatry & Neuroscience

Readers of *JPN* can subscribe to email alerts to receive the table of contents by email when a new issue appears. Sign up now at cma.ca/jpn.

Advertisers' Index

Clublink Corporation
Inside front cover
Lundbeck Canada Inc.
Cipralax MELTZ 74, 96-7
Sunovion Pharmaceuticals Canada
Latuda Outside back cover

PRESCRIBING INFORMATION
Cipralax MELTZ 138-9
Latuda 140-3